Overview

Naltrexone in the Treatment of Pyromania

Status:
Withdrawn
Trial end date:
2010-04-01
Target enrollment:
0
Participant gender:
All
Summary
The proposed study will consist of 8 weeks of treatment with either naltrexone or placebo in 10 subjects with pyromania.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Minnesota
University of Minnesota - Clinical and Translational Science Institute
Treatments:
Naltrexone
Criteria
Inclusion Criteria:

1. men and women age 16-75;

2. current DSM-IV pyromania

Exclusion Criteria:

1. unstable medical illness or clinically significant abnormalities on prestudy
laboratory tests or physical examination;

2. history of seizures;

3. myocardial infarction within 6 months;

4. current pregnancy or lactation, or inadequate contraception in women of childbearing
potential;

5. clinically significant suicidality;

6. current or recent (past 3 months) DSM-IV substance abuse or dependence;

7. illegal substance within 2 weeks of study initiation;

8. initiation of psychotherapy or behavior therapy from a mental health professional
within 3 months prior to study baseline;

9. initiation of a psychotropic medication within 2 months prior to study inclusion;

10. previous treatment with naltrexone; and

11. treatment with investigational medication or depot neuroleptics within 3 months, with
fluoxetine within 6 weeks, or with other psychotropics within 2 weeks prior to study
baseline